Phase 2 N=101 Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer
Triple-negative Breast Cancer
Primary: Number of Participants With Pathological Complete Response — 26; 28 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=18 Anakinra for Inflammatory Pustular Skin Diseases
Sneddon-Wilkinson · Acrodermatitis Continua of Hallopeau · Pustular Psoriasis
Primary: Number of Participants Treated With Anakinra Who Achieve 50% Disease Improvement by the End of Week 12, as Measured by Total Body Surface Area Involvement (TBSAI50) — 7…
Phase 2 N=196 Contezolid Acefosamil Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection
Skin Diseases, Bacterial · Gram-Positive Bacterial Infections
Primary: Early Clinical Response at the Early Assessment Visit (ITT Population) — 102; 51; 3; 6 Participants
Phase 2 N=106 Safety and Efficacy of C21 in Subjects With COVID-19
COVID-19
Primary: Change From Baseline in C-reactive Protein (CRP) After Treatment With C21 200 mg Daily Dose (100 mg b.i.d.) — 0.19; 0.22 mg/L — p==0.4891
Phase 2 N=771 To Investigate the Efficacy and Safety of OPC-6535 in Chronic Obstructive Pulmonary Disease (COPD) Patients
Chronic Obstructive Pulmonary Disease
Primary: Trough Forced Expiratory Volume in 1 Second (FEV1) Change From Baseline to 24 Months — -0.004; -0.023; -0.018; -0.035 Liters
Phase 2 N=126 Antimicrobial Efficacy of 2% CHG (Chlorhexidine Gluconate)
Healthy
Primary: Log Reduction of Bacterial Flora on the Abdomen and Groin — 1.9; 2.0; 1.3; 1.9 Log10 Reductions
Phase 2 N=108 Pilot Trial of Preoperative Chlorhexidine Gluconate (CHG) Skin Preparation
Surgery
Primary: Log Reduction of Bacterial Flora on Abdomen and Groin Sites — 2.6; 3.4; 2.7; 4.2 Log 10 Reduction
Phase 2 N=34 Perioperative Ketamine for Pain With Gastric Bypass
Laparoscopic Gastric Bypass Surgery · Ketamine
Primary: Total Cumulative Perioperative Opioid Dose — 179.9; 248.6 Morphine Equivalents — p=0.03
Phase 2 N=155 Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome
Tourette Syndrome
Primary: Frequency of Treatment-emergent Adverse Events (TEAEs) — 20; 29; 68 Participants
Phase 2 N=150 BOTOX® (onabotulinumtoxinA) Treatment of Masseter Muscle Prominence
Masseter Muscle Prominence
Primary: Percentage of Participants Who Achieved Masseter Muscle Prominence Scale (MMPS) Grade ≤ 3 at Day 90 as Assessed by the Investigator — 21.7; 90.6; 91.3 percentage of…
Phase 2 N=26 Fecal Microbiota Transplantation (FMT) in the Treatment of Pouchitis
Pouchitis · Ulcerative Colitis
Primary: Clinical Remission — 4; 5 Participants — p=0.183
Phase 2 N=12 Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL)
Chronic Hepatitis C
Primary: Number of Subjects With Treatment Emergent Adverse Events — 10 Participants
Phase 2 N=100 Safety and Efficacy of ORM-12741 in Patients With Alzheimer's Disease
Alzheimer's Disease
Primary: Number of Participants With Adverse Events — 18; 21; 21 Participants
Phase 2 N=23 Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease
Stargardt Disease · Macular Atrophy
Primary: Change in Electrical Response of the Retina to a Flash of Light, as Measured by Electroretinogram — -12.23; 68.00; 96.69 percent suppression
Phase 2 N=113 Trial of Clopidogrel After Surgery for Coronary Artery Disease (CASCADE Trial)
Atherosclerosis
Primary: Vein Graft Intimal Area — 4.1; 4.5 mm